Surface decorated reporter-tagged chikungunya virus-like particles for clinical diagnostics and identification of virus entry inhibitors

Singh, Vedita Anand; Kumar, Chandra Shekhar; Khare, Baldeep; Kühn, Richard; Banerjee, Manidipa; Tomar, Shailly

doi:10.1016/j.virol.2022.11.012

Cited by 2 publications

(4 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like other alphaviruses, Chikungunya virus can infect a wide variety of cells and tissues as the receptor for CHIKV is ubiquitously expressed in host cells. In a previous study, it has been shown that the mCherry insertion at N-terminal of E2 did not cause significant defects in virus assembly and entry (40, 46). Our ChAC-VLP vector design is such the multimeric epitopes (RBD-E2) is exposed on the surface of VLPs.…”

Section: Resultsmentioning

confidence: 94%

“…Even at low doses of ChAC-VLP, the chimeric immune response is generated. The merits of using chimeric VLP as vaccine is the antigen presentation as multiple copies on surface of VLPs as in ChAC-VLP plasmid design, 1:1 incorporation of RBD-E2 is ensured as per previously reported study on reporter-tagged chikungunya virus-like particles (40) and fluorescent protein-tagged Sindbis virus E2 glycoprotein (48). ELISA and SPR was performed to analyse and validate RBD-specific antibody generated in immunized mice sera.…”

Section: Resultsmentioning

confidence: 99%

“…The post-chikungunya status shows similarities with the long-term effects of the COVID-19 infection in terms of socio-economic effects and overall disease burden (39). Currently, licenced no antiviral therapy or vaccine is available for any alphavirus infection worldwide (40)(41)(42). Hence, the only effective way to control the spread of these viral infection is through vaccinations in endemic areas and the most vulnerable populations.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Chimeric chikungunya virus-like particles with surface exposed SARS-CoV-2 RBD elicits potent immunogenic responses in mice

Singh

Nehul

Kumar

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic has reinforced efforts for developing effective vaccination strategy for existing and emerging viruses. Currently there are various vaccine technology available for treating viral diseases, however it is imperative to develop and investigate second-generation vaccines such as chimeric virus-like particles (chi-VLPs) vaccine for increased immunogenicity, ease of production and scalability to supplement the worldwide vaccine supply. Intriguingly, chi-VLPs expresses more than one antigenic epitope on its surface, hence it is expected to be a more effective vaccine candidate. Hereby, this study reports, a novel bivalent vaccine design of chimeric alphavirus coronavirus virus-like particles (ChAC-VLPs), displaying fusion glycoproteins of CHIKV and receptor binding domain (RBD) of SARS-CoV-2 on its surface. Uniqueness and versatility of ChAC-VLPs has been demonstrated via a various techniques including Western blot, Immunofluorescence, cryoEM, and dynamic light scattering (DLS). The multimeric epitope display of immunogenic antigens, i.e CHIKV envelop glycoprotein and SARS-CoV-2 RBD was validated by cell-based assays. ChAC-VLP immunized mice has shown substantial neutralization titres for CHIKV (PRNT50 of 1:25) from the serum collected after 2ndbooster doses. Similarly, serum antibodies were detected for SARS-CoV2 RBD as observed by antigen specific ELISA and validated using surface plasmon resonance (SPR). SPR binding response was detected to be >200 RU for anti-RBD antibody in post-immunized mice sera. In conclusion, present study proposes ChAC-VLPs as a potential hybrid vaccine candidate for CHIKV and SARS-CoV-2 infection and contributes valuable insights in chi-VLPs domain.

show abstract

Section: Resultsmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chimeric chikungunya virus-like particles with surface exposed SARS-CoV-2 RBD elicits potent immunogenic responses in mice

Singh

Nehul

Kumar

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Besides, Tomar and colleagues from IITR recently developed tamarind chitinase (chi)-like lectin glycan-based virus capture assay as a point-of-care routine diagnostic and titration assay for CHIKV as well as for other re-emerging alphaviral infections [ 153 ]. Moreover, they recently reported that exploiting NLuc CHIK-VLPs as a detector probe offers the potential for large-scale screening of samples [ 154 ]. Further, Sunil’s group evaluated the immunochromatographic rapid diagnosis kit for the detection of CHIKV antigen in the country and performed serological, virological, and clinical analyses of people infected with the virus [ 64 , 155 , 156 , 157 ].…”

Section: Chikv Research: Indian Scenariomentioning

confidence: 99%

An Overview of Indian Biomedical Research on the Chikungunya Virus with Particular Reference to Its Vaccine, an Unmet Medical Need

et al. 2023

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) is an infectious agent spread by mosquitos, that has engendered endemic or epidemic outbreaks of Chikungunya fever (CHIKF) in Africa, South-East Asia, America, and a few European countries. Like most tropical infections, CHIKV is frequently misdiagnosed, underreported, and underestimated; it primarily affects areas with limited resources, like developing nations. Due to its high transmission rate and lack of a preventive vaccine or effective treatments, this virus poses a serious threat to humanity. After a 32-year hiatus, CHIKV reemerged as the most significant epidemic ever reported, in India in 2006. Since then, CHIKV-related research was begun in India, and up to now, more than 800 peer-reviewed research papers have been published by Indian researchers and medical practitioners. This review gives an overview of the outbreak history and CHIKV-related research in India, to favor novel high-quality research works intending to promote effective treatment and preventive strategies, including vaccine development, against CHIKV infection.

show abstract

Surface decorated reporter-tagged chikungunya virus-like particles for clinical diagnostics and identification of virus entry inhibitors

Cited by 2 publications

References 90 publications

Chimeric chikungunya virus-like particles with surface exposed SARS-CoV-2 RBD elicits potent immunogenic responses in mice

Chimeric chikungunya virus-like particles with surface exposed SARS-CoV-2 RBD elicits potent immunogenic responses in mice

An Overview of Indian Biomedical Research on the Chikungunya Virus with Particular Reference to Its Vaccine, an Unmet Medical Need

Contact Info

Product

Resources

About